Agios to Participate in March Investor Conferences
03 March 2023 - 12:26AM
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field
of cellular metabolism pioneering therapies for rare diseases,
today announced that the company is scheduled to present at the
following March investor conferences:
- Cowen 43rd Annual Health Care Conference on Monday, March 6,
2023 at 1:30 p.m. ET; and
- Oppenheimer 33rd Annual Healthcare Conference on Monday, March
13, 2023 at 12:00 p.m. ET.
Live webcasts of the presentations can be accessed
under "Events & Presentations" in the Investors section of the
company's website at www.agios.com. Replays of the webcasts will be
archived on the Agios website for at least two weeks following each
presentation.
About AgiosAgios is a
biopharmaceutical company that is fueled by connections. The Agios
team cultivates strong bonds with patient communities, healthcare
professionals, partners and colleagues to discover, develop and
deliver therapies for rare diseases. In the U.S., Agios markets a
first-in-class pyruvate kinase (PK) activator for adults with PK
deficiency, the first disease-modifying therapy for this rare,
lifelong, debilitating hemolytic anemia. Building on the company's
leadership in the field of cellular metabolism, Agios is advancing
a robust clinical pipeline of investigational medicines with
programs in alpha- and beta-thalassemia, sickle cell disease,
pediatric PK deficiency and MDS-associated anemia. In addition to
its clinical pipeline, Agios has a PAH stabilizer in preclinical
development as a potential treatment for phenylketonuria (PKU) and
deep scientific expertise in classical hematology. For more
information, please visit the company’s website at
www.agios.com.
Investor & Media
ContactJessica RennekampSenior Director, Corporate
CommunicationsJessica.Rennekamp@agios.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Apr 2023 to Apr 2024